Exclusive Summary

• Broad indications and massive patient base: Covers Major Depressive Disorder (~280 million globally) and Diabetic Peripheral Neuropathic Pain (tens of millions globally), ensuring rigid and growing market demand.
• First-line clinical standard: As a flagship SNRI, it is recommended as a first-line treatment for depression and chronic pain by APA, NICE, and ADA guidelines; the 30mg strength is the standard starting and titration dose, ensuring a high prescription turnover rate.
• Technical barrier combined with high margins: The enteric-coated pellet technology presents a manufacturing barrier (ensuring gastric stability); backed by China's scalable supply chain, it offers distributors significant cost advantages and generous profit margins.
• Zero IP risk for rapid commercialization: The originator's (Cymbalta) patents have expired globally, allowing distributors to leverage the Distribution model to quickly capture market share in local tenders and commercial markets without patent infringement risks.